HC Wainwright Forecasts Strong Price Appreciation for Atossa Therapeutics (NASDAQ:ATOS) Stock

Atossa Therapeutics (NASDAQ:ATOS) had its price target increased by HC Wainwright from $6.00 to $7.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th.

Atossa Therapeutics Price Performance

Shares of Atossa Therapeutics stock opened at $1.28 on Wednesday. The stock has a market cap of $160.97 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. The firm’s 50-day moving average is $1.44 and its 200 day moving average is $1.38. Atossa Therapeutics has a 1 year low of $0.65 and a 1 year high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ATOS. XTX Topco Ltd bought a new position in Atossa Therapeutics during the 2nd quarter valued at about $29,000. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics in the 3rd quarter worth approximately $29,000. SG Americas Securities LLC lifted its stake in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. Cetera Advisors LLC bought a new position in shares of Atossa Therapeutics in the 1st quarter worth approximately $72,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Atossa Therapeutics in the 3rd quarter worth approximately $75,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.